| Symbol | IPHYF |
|---|---|
| Name | INNATE PHARMA |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | - |
| Address | 13 009 France 117, Avenue de Luminy - BP 30191 |
| Telephone | + 33 (0) 4 30 30 30 |
| Fax | — |
| — | |
| Website | http://www.innate-pharma.com/ |
| Incorporation | UNDEFINED |
| Incorporated On | 1999 |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC;NASDAQ |
| Auditor | Deloitte et Associes; |
| Audit Status | AUDITED |
| Reporting Status | U.S. Reporting: SEC Reporting |
| CIK | 0001598599 |
| Description | Innate Pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by enhancing the capability of the bodys own immune cells to recognize and kill cancer cells. The Company has pioneered the development of antibodies that block inhibitory checkpoint receptors on NK cells. Today, Innate Pharma has three first-in-class antibodies in clinical development in immuno-oncology and a pipeline of preclinical candidates to novel targets and mechanisms. Its innovative approach has translated into alliances with leaders in the biopharmaceutical industry such as AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S and Sanofi. Based in Marseille, France, Innate Pharma had 122 employees as at March 31, 2016. The company is listed on Euronext Paris. Additional info from NASDAQ: Additional info from OTC: The Company has pioneered the development of antibodies that block inhibitory checkpoint receptors on NK cells. Today, Innate Pharma has three first-in-class antibodies in clinical development in immuno-oncology and a pipeline of preclinical candidates to novel targets and mechanisms. Its innovative approach has translated into alliances with leaders in the biopharmaceutical industry such as AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S and Sanofi. Based in Marseille, France, Innate Pharma had 122 employees as at March 31, 2016. The company is listed on Euronext Paris. |
2026-03-04 18:45
New Form SCHEDULE 13G/A - Innate Pharma SA <b>Filed:</b> 2026-03-04 <b>AccNo:</b> 0000950103-26-003227 <b>Size:</b> 6 KB
Read more
2026-02-06 11:49
New Form SCHEDULE 13D/A - Innate Pharma SA <b>Filed:</b> 2026-02-06 <b>AccNo:</b> 0001104659-26-011298 <b>Size:</b> 42 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07367295 | Prospective Clinical Study, Using a Medical Device (RepHegyn) as an Adjuvant in… | — | Bacterial Infections | Not_Yet_Recruiting | 2026-05-01 | 2026-08-01 | ClinicalTrials.gov |
| NCT07539194 | Evaluation of the Performance and Safety of a Single-dose Hyaluronic Acid (Prom… | Na | Meniscus Tears | Recruiting | 2026-04-30 | 2027-01-30 | ClinicalTrials.gov |
| NCT06594393 | A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study | Phase2 | Epidermolysis Bullosa (EB) | Recruiting | 2026-01-30 | 2027-06-30 | ClinicalTrials.gov |
| NCT07196514 | Effects of 8 Weeks of Turmeric Ingestion on Physiology and Wellbeing in Healthy… | Na | Turmeric | Recruiting | 2025-10-06 | 2026-07-01 | ClinicalTrials.gov |
| NCT07367061 | Clinical Investigation to Assess Safety and Efficacy of INNEA AQUA in Adult Wom… | Na | Vulvo Vaginal Atrophy | Active_Not_Recruiting | 2025-09-25 | 2026-06-30 | ClinicalTrials.gov |
| NCT06781983 | Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors | Phase1 | Advanced or Metastatic Solid Tumors | Recruiting | 2025-01-24 | 2029-04-01 | ClinicalTrials.gov |
| NCT07468539 | Post-exercise Rehydration: A Randomised Cross-over Trial Comparing a 100% Fruit… | Na | Dehydration | Completed | 2024-11-08 | 2025-05-22 | ClinicalTrials.gov |
| NCT06088654 | Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodg… | Phase1 | Non Hodgkin Lymphoma | Terminated | 2024-03-04 | 2026-02-06 | ClinicalTrials.gov |
| NCT05742607 | IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (… | Phase2 | Non Small Cell Lung Cancer | Recruiting | 2023-06-23 | 2027-06-01 | ClinicalTrials.gov |
| NCT07331181 | Evaluation of Performance and Safety of INNEA and INNEA AQUA for the Treatment … | Na | Wrinkle | Recruiting | 2023-06-01 | 2026-12-30 | ClinicalTrials.gov |
| NCT05378997 | Safety, Tolerability, and Pharmacokinetics of Ascending Topical Doses of TCP-25… | Phase1 | Blister | Completed | 2022-04-07 | 2024-03-16 | ClinicalTrials.gov |
| NCT05242822 | A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGF… | Phase1 | Solid Tumor, Adult | Terminated | 2022-03-29 | 2024-10-03 | ClinicalTrials.gov |
| NCT05321147 | Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Periphera… | Phase1 | Peripheral T Cell Lymphoma | Completed | 2022-03-17 | 2024-02-08 | ClinicalTrials.gov |
| NCT05143970 | A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination… | Phase1 | Metastatic Cancer | Active_Not_Recruiting | 2022-01-21 | 2027-03-01 | ClinicalTrials.gov |
| NCT04984837 | Study of Lacutamab in Peripheral T-cell Lymphoma | Phase2 | Peripheral T Cell Lymphoma | Active_Not_Recruiting | 2021-10-05 | 2028-04-30 | ClinicalTrials.gov |
| NCT04371367 | Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia (… | Phase2 | COVID | Completed | 2020-04-27 | 2021-03-30 | ClinicalTrials.gov |
| NCT04369820 | C5a Receptor Expression - COVID-19 (C5-COV) | Na | COVID-19 | Completed | 2020-03-31 | 2023-08-09 | ClinicalTrials.gov |
| NCT03902184 | IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Ad… | Phase2 | Lymphoma, T-Cell | Completed | 2019-05-22 | 2026-01-08 | ClinicalTrials.gov |
| NCT03665129 | IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced So… | Phase1 | Advanced Solid Tumors | Terminated | 2018-09-07 | 2021-02-24 | ClinicalTrials.gov |
| NCT03307941 | Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally … | Phase1 | Adenocarcinoma of the Esophagus | Withdrawn | 2017-07-20 | 2017-12-11 | ClinicalTrials.gov |
| NCT03311100 | Immunological Profile of Solid Tumors Sample | — | Solid Cancer | Unknown | 2017-04-06 | 2020-04-06 | ClinicalTrials.gov |
| NCT03015038 | Study of the Immune Response in Colon Adenocarcinoma | — | Colon Adenocarcinoma | Completed | 2017-02-05 | 2024-02-05 | ClinicalTrials.gov |
| NCT02921685 | Study of a Humanized Antibody Initiated 2 Months After an HLA Matched Allogenic… | Phase1 | Hematologic Malignancies | Unknown | 2016-11-28 | 2020-04-28 | ClinicalTrials.gov |
| NCT02643550 | Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squ… | Phase1 | Head and Neck Neoplasms | Completed | 2015-12-01 | 2023-03-28 | ClinicalTrials.gov |
| NCT02557516 | Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refracto… | Phase1 | Chronic Lymphocytic Leukemia | Terminated | 2015-11-09 | 2019-09-25 | ClinicalTrials.gov |
| NCT02593045 | Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma… | Phase1 | Cutaneous T-Cell Lymphoma | Completed | 2015-10-01 | 2020-04-01 | ClinicalTrials.gov |
| NCT02459301 | A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies | Phase1 | Gynecologic Cancer | Completed | 2015-09-17 | 2019-11-12 | ClinicalTrials.gov |
| NCT02434276 | Study of the Immunogenicity and Safety of a Quadrivalent Influenza Vaccine (VAX… | Phase2 | Influenza | Unknown | 2015-05-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT02331875 | Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinom… | Phase1 | Squamous Cell Carcinoma of the Oral Cavity | Terminated | 2014-12-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02247362 | Study of Safety and Immunogenicity of a Quadrivalent Influenza Vaccine in Healt… | Phase1 | Influenza | Unknown | 2014-11-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT02228213 | Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Scl… | Phase2 | Secondary Progressive Multiple Sclerosis | Completed | 2014-10-01 | 2017-06-01 | ClinicalTrials.gov |
| NCT02015494 | Phase 1 Safety Study of Recombinant Influenza Vaccine for Prevention | Phase1 | Influenza | Unknown | 2014-03-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT01687387 | Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acut… | Phase2 | Acute Myeloid Leukemia | Completed | 2012-10-01 | 2016-11-17 | ClinicalTrials.gov |
| NCT01658800 | Study of the Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Hea… | Phase1 | Influenza | Completed | 2012-09-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01560793 | Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults A… | Phase1 | Influenza | Completed | 2012-06-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01370902 | Safety and Tolerability of NNC0141-0000-0100 in Subjects With Rheumatoid Arthri… | Phase1 | Inflammation | Completed | 2011-05-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01217203 | Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined W… | Phase1 | Patients With Multiple Myeloma Experiencing a | Completed | 2010-09-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01222286 | Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patient… | Phase2 | Smoldering Multiple Myeloma | Completed | 2010-09-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01172054 | Comparative Safety and Immunogenicity of VAX128A, VAC128B and VAX128C Novel H1N… | Phase1 | Influenza | Completed | 2010-07-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT00999830 | Evaluation of Activity, Safety and Pharmacology of IPH2101 a Human Monoclonal A… | Phase2 | Multiple Myeloma | Completed | 2009-09-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT00921947 | Comparative Safety and Immunogenicity of 1.0 µg Intramuscular (i.m.) and 2.0 µg… | Phase1 | Influenza | Completed | 2009-06-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00921206 | Study to Investigate the Immune Response to Two Doses of VAX102 Healthy Adults | Phase1 | Influenza | Completed | 2009-06-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00562666 | Immunotherapy of Hepatocellular Carcinoma With Gamma Delta T Cells | Phase1 | Hepatocellular Carcinoma | Terminated | 2008-02-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00552396 | An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR… | Phase1 | Multiple Myeloma | Completed | 2007-05-01 | 2011-01-01 | ClinicalTrials.gov |
| NCT01256073 | A Safety and Tolerability Extension Trial Assessing Repeated Dosing of Anti-KIR… | Phase1 | Acute Myeloid Leukemia | Completed | 2007-02-01 | 2013-09-01 | ClinicalTrials.gov |
Total clinical trials: 45
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| IPH5301 ALONE OR IN COMBINATION WITH CHEMOTHERAPY AND TRASTUZUMAB | Drug | Phase PHASE1 | Metastatic Cancer | ACTIVE_NOT_RECRUITING | NCT05143970 |
| IPH5201 + durvalumab + standard chemotherapy | Drug | Phase PHASE2 | Non Small Cell Lung Cancer | RECRUITING | NCT05742607 |
| Oxaliplatine | Other | Phase PHASE2 | Peripheral T Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04984837 |
| Gemcitabine | Other | Phase PHASE2 | Peripheral T Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04984837 |
| Lacutamab | Other | Phase PHASE2 | Peripheral T Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04984837 |
| Vehicle (placebo) | Other | Phase PHASE2 | Epidermolysis Bullosa (EB) | RECRUITING | NCT06594393 |
| TCP-25 gel | Other | Phase PHASE2 | Epidermolysis Bullosa (EB) | RECRUITING | NCT06594393 |
| Vehicle (placebo) | Other | Phase PHASE2 | Epidermolysis Bullosa (EB) | RECRUITING | NCT06594393 |
| TCP-25 gel | Other | Phase PHASE2 | Epidermolysis Bullosa (EB) | RECRUITING | NCT06594393 |
| Vehicle (placebo) | Other | Phase PHASE2 | Epidermolysis Bullosa (EB) | RECRUITING | NCT06594393 |
| TCP-25 gel | Other | Phase PHASE2 | Epidermolysis Bullosa (EB) | RECRUITING | NCT06594393 |
| Vehicle (placebo) | Other | Phase PHASE2 | Epidermolysis Bullosa (EB) | RECRUITING | NCT06594393 |
| TCP-25 gel | Other | Phase PHASE2 | Epidermolysis Bullosa (EB) | RECRUITING | NCT06594393 |
| Vehicle (placebo) | Other | Phase PHASE2 | Epidermolysis Bullosa (EB) | RECRUITING | NCT06594393 |
| TCP-25 gel | Other | Phase PHASE2 | Epidermolysis Bullosa (EB) | RECRUITING | NCT06594393 |
| Vehicle (placebo) | Other | Phase PHASE2 | Epidermolysis Bullosa (EB) | RECRUITING | NCT06594393 |
| TCP-25 gel | Other | Phase PHASE2 | Epidermolysis Bullosa (EB) | RECRUITING | NCT06594393 |
| Vehicle (placebo) | Other | Phase PHASE2 | Epidermolysis Bullosa (EB) | RECRUITING | NCT06594393 |
| TCP-25 gel | Other | Phase PHASE2 | Epidermolysis Bullosa (EB) | RECRUITING | NCT06594393 |
| Vehicle (placebo) | Other | Phase PHASE2 | Epidermolysis Bullosa (EB) | RECRUITING | NCT06594393 |
| TCP-25 gel | Other | Phase PHASE2 | Epidermolysis Bullosa (EB) | RECRUITING | NCT06594393 |
| Vehicle (placebo) | Other | Phase PHASE2 | Epidermolysis Bullosa (EB) | RECRUITING | NCT06594393 |
| TCP-25 gel | Other | Phase PHASE2 | Epidermolysis Bullosa (EB) | RECRUITING | NCT06594393 |
| Vehicle (placebo) | Other | Phase PHASE2 | Epidermolysis Bullosa (EB) | RECRUITING | NCT06594393 |
| TCP-25 gel | Other | Phase PHASE2 | Epidermolysis Bullosa (EB) | RECRUITING | NCT06594393 |
| Vehicle (placebo) | Other | Phase PHASE2 | Epidermolysis Bullosa (EB) | RECRUITING | NCT06594393 |
| TCP-25 gel | Other | Phase PHASE2 | Epidermolysis Bullosa (EB) | RECRUITING | NCT06594393 |
| Vehicle (placebo) | Other | Phase PHASE2 | Epidermolysis Bullosa (EB) | RECRUITING | NCT06594393 |
| TCP-25 gel | Other | Phase PHASE2 | Epidermolysis Bullosa (EB) | RECRUITING | NCT06594393 |
| IPH2101 | Other | Phase PHASE2 | Smoldering Multiple Myeloma | COMPLETED | NCT01222286 |
| IPH2101 | Other | Phase PHASE2 | Smoldering Multiple Myeloma | COMPLETED | NCT01222286 |
| IPH2101 | Other | Phase PHASE2 | Smoldering Multiple Myeloma | COMPLETED | NCT01222286 |
| IPH2101 | Other | Phase PHASE2 | Smoldering Multiple Myeloma | COMPLETED | NCT01222286 |
| IPH2101 | Other | Phase PHASE2 | Smoldering Multiple Myeloma | COMPLETED | NCT01222286 |
| IPH2101 | Other | Phase PHASE2 | Smoldering Multiple Myeloma | COMPLETED | NCT01222286 |
| IPH2101 | Other | Phase PHASE2 | Smoldering Multiple Myeloma | COMPLETED | NCT01222286 |
| IPH2101 | Other | Phase PHASE2 | Smoldering Multiple Myeloma | COMPLETED | NCT01222286 |
| VAX2012Q | Other | Phase PHASE1 | Influenza | UNKNOWN | NCT02015494 |
| VAX2012Q | Other | Phase PHASE1 | Influenza | UNKNOWN | NCT02015494 |
| VAX102 | Other | Phase PHASE1 | Influenza | COMPLETED | NCT00921947 |
| VAX102 | Other | Phase PHASE1 | Influenza | COMPLETED | NCT00921947 |
| Placebo | Other | Phase PHASE1 | Influenza | COMPLETED | NCT01172054 |
| VAX128 | Other | Phase PHASE1 | Influenza | COMPLETED | NCT01172054 |
| Placebo | Other | Phase PHASE1 | Influenza | COMPLETED | NCT01172054 |
| VAX128 | Other | Phase PHASE1 | Influenza | COMPLETED | NCT01172054 |
| IPH2101 | Other | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT01256073 |
| IPH2101 combined to lenalidomide | Other | Phase PHASE1 | Patients With Multiple Myeloma Experiencing a | COMPLETED | NCT01217203 |
| IPH2101 | Other | Phase PHASE2 | Smoldering Multiple Myeloma | COMPLETED | NCT01222286 |
| VAX161 [STF2.HA5 H5N1] | Other | Phase PHASE1 | Influenza | COMPLETED | NCT01560793 |
| VAX161 [STF2.HA5 H5N1] | Other | Phase PHASE1 | Influenza | COMPLETED | NCT01560793 |
| VAX102 | Other | Phase PHASE1 | Influenza | COMPLETED | NCT00921206 |
| VAX102 | Other | Phase PHASE1 | Influenza | COMPLETED | NCT00921206 |
| placebo | Other | Phase PHASE1 | Inflammation | COMPLETED | NCT01370902 |
| NNC 0141-0000-0100 | Other | Phase PHASE1 | Inflammation | COMPLETED | NCT01370902 |
| VAX161C vaccine | Other | Phase PHASE1 | Influenza | COMPLETED | NCT01658800 |
| VAX161C vaccine | Other | Phase PHASE1 | Influenza | COMPLETED | NCT01658800 |
| Placebo | Other | Phase PHASE1 | Influenza | UNKNOWN | NCT02247362 |
| VAX2012Q | Other | Phase PHASE1 | Influenza | UNKNOWN | NCT02247362 |
| Placebo | Other | Phase PHASE1 | Influenza | UNKNOWN | NCT02247362 |
| VAX2012Q | Other | Phase PHASE1 | Influenza | UNKNOWN | NCT02247362 |
| Fluzone Quadrivalent | Other | Phase PHASE2 | Influenza | UNKNOWN | NCT02434276 |
| VAX2012Q | Other | Phase PHASE2 | Influenza | UNKNOWN | NCT02434276 |
| Fluzone Quadrivalent | Other | Phase PHASE2 | Influenza | UNKNOWN | NCT02434276 |
| VAX2012Q | Other | Phase PHASE2 | Influenza | UNKNOWN | NCT02434276 |
| IPH2101 | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT00999830 |
| Postsurgical Adjuvant Therapy | Drug | Phase PHASE1 | Squamous Cell Carcinoma of the Oral Cavity | TERMINATED | NCT02331875 |
| Standard Surgery | Procedure | Phase PHASE1 | Squamous Cell Carcinoma of the Oral Cavity | TERMINATED | NCT02331875 |
| IPH2201 | Other | Phase PHASE1 | Squamous Cell Carcinoma of the Oral Cavity | TERMINATED | NCT02331875 |
| Saline | Other | Phase PHASE2 | Secondary Progressive Multiple Sclerosis | COMPLETED | NCT02228213 |
| MIS416 | Other | Phase PHASE2 | Secondary Progressive Multiple Sclerosis | COMPLETED | NCT02228213 |
| Saline | Other | Phase PHASE2 | Secondary Progressive Multiple Sclerosis | COMPLETED | NCT02228213 |
| MIS416 | Other | Phase PHASE2 | Secondary Progressive Multiple Sclerosis | COMPLETED | NCT02228213 |
| Surgery | Procedure | Phase PHASE1 | Adenocarcinoma of the Esophagus | WITHDRAWN | NCT03307941 |
| Metabolic | Other | Phase PHASE1 | Adenocarcinoma of the Esophagus | WITHDRAWN | NCT03307941 |
| 5-Fluorouracil | Other | Phase PHASE1 | Adenocarcinoma of the Esophagus | WITHDRAWN | NCT03307941 |
| Oxaliplatin | Other | Phase PHASE1 | Adenocarcinoma of the Esophagus | WITHDRAWN | NCT03307941 |
| Monalizumab | Other | Phase PHASE1 | Adenocarcinoma of the Esophagus | WITHDRAWN | NCT03307941 |
| immunohistochemistry assay | Other | Preclinical | Solid Cancer | UNKNOWN | NCT03311100 |
| Monalizumab | Other | Phase PHASE1 | Hematologic Malignancies | UNKNOWN | NCT02921685 |
| Placebo (normal saline solution) | Other | Phase PHASE2 | Acute Myeloid Leukemia | COMPLETED | NCT01687387 |
| IPH2102 at 1 mg/kg | Other | Phase PHASE2 | Acute Myeloid Leukemia | COMPLETED | NCT01687387 |
| IPH2102 at 0.1 mg/kg | Other | Phase PHASE2 | Acute Myeloid Leukemia | COMPLETED | NCT01687387 |
| monalizumab | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | TERMINATED | NCT02557516 |
| IPH4102 | Other | Phase PHASE1 | Cutaneous T-Cell Lymphoma | COMPLETED | NCT02593045 |
| Placebo | Other | Phase PHASE2 | COVID | COMPLETED | NCT04371367 |
| avdoralimab | Other | Phase PHASE2 | COVID | COMPLETED | NCT04371367 |
| IPH5401 and Durvalumab | Other | Phase PHASE1 | Advanced Solid Tumors | TERMINATED | NCT03665129 |
| Anti-PD(L)1 | Other | Phase PHASE1 | Head and Neck Neoplasms | COMPLETED | NCT02643550 |
| Cetuximab | Other | Phase PHASE1 | Head and Neck Neoplasms | COMPLETED | NCT02643550 |
| Monalizumab | Other | Phase PHASE1 | Head and Neck Neoplasms | COMPLETED | NCT02643550 |
| IPH2201 | Other | Phase PHASE1 | Gynecologic Cancer | COMPLETED | NCT02459301 |
| draw blood | Other | Approved | COVID-19 | COMPLETED | NCT04369820 |
| TCP-25 gel 8.6 mg/ml or placebo gel | Other | Phase PHASE1 | Blister | COMPLETED | NCT05378997 |
| TCP-25 gel 2.9 mg/ml or placebo gel | Other | Phase PHASE1 | Blister | COMPLETED | NCT05378997 |
| TCP-25 gel 0.86 mg/ml or placebo gel | Other | Phase PHASE1 | Blister | COMPLETED | NCT05378997 |
| TCP-25 gel 8.6 mg/ml or placebo gel | Other | Phase PHASE1 | Blister | COMPLETED | NCT05378997 |
| TCP-25 gel 2.9 mg/ml or placebo gel | Other | Phase PHASE1 | Blister | COMPLETED | NCT05378997 |
| TCP-25 gel 0.86 mg/ml or placebo gel | Other | Phase PHASE1 | Blister | COMPLETED | NCT05378997 |
| lacutamab | Other | Phase PHASE1 | Peripheral T Cell Lymphoma | COMPLETED | NCT05321147 |
| KIN-3248 | Other | Phase PHASE1 | Solid Tumor, Adult | TERMINATED | NCT05242822 |
| KIN-3248 | Other | Phase PHASE1 | Solid Tumor, Adult | TERMINATED | NCT05242822 |
| IPH5201 + durvalumab + standard chemotherapy | Drug | Phase PHASE2 | Non Small Cell Lung Cancer | RECRUITING | NCT05742607 |
| arm 2: standard of care | Other | Approved | Vulvo Vaginal Atrophy | ACTIVE_NOT_RECRUITING | NCT07367061 |
| product: Innea Aqua vaginal use | Other | Approved | Vulvo Vaginal Atrophy | ACTIVE_NOT_RECRUITING | NCT07367061 |
| arm 2: standard of care | Other | Approved | Vulvo Vaginal Atrophy | ACTIVE_NOT_RECRUITING | NCT07367061 |
| product: Innea Aqua vaginal use | Other | Approved | Vulvo Vaginal Atrophy | ACTIVE_NOT_RECRUITING | NCT07367061 |
| IPH4502 | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | RECRUITING | NCT06781983 |
| Placebo | Other | Approved | Turmeric | RECRUITING | NCT07196514 |
| Raw turmeric shots | Other | Approved | Turmeric | RECRUITING | NCT07196514 |
| Placebo | Other | Approved | Turmeric | RECRUITING | NCT07196514 |
| Raw turmeric shots | Other | Approved | Turmeric | RECRUITING | NCT07196514 |
| Placebo | Other | Approved | Turmeric | RECRUITING | NCT07196514 |
| Raw turmeric shots | Other | Approved | Turmeric | RECRUITING | NCT07196514 |
| Fruit beverage | Other | Approved | Dehydration | COMPLETED | NCT07468539 |
| Glucose-based sports drink | Other | Approved | Dehydration | COMPLETED | NCT07468539 |
| Water | Other | Approved | Dehydration | COMPLETED | NCT07468539 |
| Fruit beverage | Other | Approved | Dehydration | COMPLETED | NCT07468539 |
| Glucose-based sports drink | Other | Approved | Dehydration | COMPLETED | NCT07468539 |
| Water | Other | Approved | Dehydration | COMPLETED | NCT07468539 |
| Fruit beverage | Other | Approved | Dehydration | COMPLETED | NCT07468539 |
| Glucose-based sports drink | Other | Approved | Dehydration | COMPLETED | NCT07468539 |
| Water | Other | Approved | Dehydration | COMPLETED | NCT07468539 |
| Placebo | Other | Phase PHASE3 | Squamous Cell Carcinoma of the Head and Neck | ACTIVE_NOT_RECRUITING | NCT04590963 |
| Cetuximab | Other | Phase PHASE3 | Squamous Cell Carcinoma of the Head and Neck | ACTIVE_NOT_RECRUITING | NCT04590963 |
| Monalizumab | Other | Phase PHASE3 | Squamous Cell Carcinoma of the Head and Neck | ACTIVE_NOT_RECRUITING | NCT04590963 |
| IPH5301 ALONE OR IN COMBINATION WITH CHEMOTHERAPY AND TRASTUZUMAB | Drug | Phase PHASE1 | Metastatic Cancer | RECRUITING | NCT05143970 |
| IPH6501 | Other | Phase PHASE1 | Non Hodgkin Lymphoma | TERMINATED | NCT06088654 |
| Innea, Innea Aqua | Other | Approved | Wrinkle | RECRUITING | NCT07331181 |
| Promovia Hydro Balance 100 mg, Hyaluronic acid sodium salt and trehalose | Other | Approved | Meniscus Tears | RECRUITING | NCT07539194 |
| Promovia Hydro Balance 100 mg, Hyaluronic acid sodium salt and trehalose | Other | Approved | Meniscus Tears | RECRUITING | NCT07539194 |
| Oxaliplatine | Other | Phase PHASE2 | Peripheral T Cell Lymphoma | RECRUITING | NCT04984837 |
| Gemcitabine | Other | Phase PHASE2 | Peripheral T Cell Lymphoma | RECRUITING | NCT04984837 |
| Lacutamab | Other | Phase PHASE2 | Peripheral T Cell Lymphoma | RECRUITING | NCT04984837 |
| IPH4102 | Other | Phase PHASE2 | Lymphoma, T-Cell | COMPLETED | NCT03902184 |
| IPH4102 | Other | Phase PHASE2 | Lymphoma, T-Cell | COMPLETED | NCT03902184 |
| IPH4102 | Other | Phase PHASE2 | Lymphoma, T-Cell | COMPLETED | NCT03902184 |
| IPH4102 | Other | Phase PHASE2 | Lymphoma, T-Cell | COMPLETED | NCT03902184 |
| IPH4102 | Other | Phase PHASE2 | Lymphoma, T-Cell | COMPLETED | NCT03902184 |
| IPH4102 | Other | Phase PHASE2 | Lymphoma, T-Cell | COMPLETED | NCT03902184 |
| IPH4102 | Other | Phase PHASE2 | Lymphoma, T-Cell | COMPLETED | NCT03902184 |
| IPH4102 | Other | Phase PHASE2 | Lymphoma, T-Cell | COMPLETED | NCT03902184 |
| IPH4102 | Other | Phase PHASE2 | Lymphoma, T-Cell | COMPLETED | NCT03902184 |
| IPH4102 | Other | Phase PHASE2 | Lymphoma, T-Cell | COMPLETED | NCT03902184 |
| IPH4102 | Other | Phase PHASE2 | Lymphoma, T-Cell | COMPLETED | NCT03902184 |
| IPH4102 | Other | Phase PHASE2 | Lymphoma, T-Cell | COMPLETED | NCT03902184 |
| Innea, Innea Aqua | Other | Approved | Wrinkle | RECRUITING | NCT07331181 |
| Innea, Innea Aqua | Other | Approved | Wrinkle | RECRUITING | NCT07331181 |
| Innea, Innea Aqua | Other | Approved | Wrinkle | RECRUITING | NCT07331181 |
| Innea, Innea Aqua | Other | Approved | Wrinkle | RECRUITING | NCT07331181 |
| IPH4502 | DRUG | Phase PHASE1 | Advanced or Metastatic Solid Tumors | RECRUITING | NCT06781983 |
| IPH6501 | DRUG | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06088654 |
| IPH5201 + durvalumab + standard chemotherapy | DRUG | Phase PHASE2 | Non Small Cell Lung Cancer | RECRUITING | NCT05742607 |
| lacutamab | BIOLOGICAL | Phase PHASE1 | Peripheral T Cell Lymphoma | COMPLETED | NCT05321147 |
| KIN-3248 | DRUG | Phase PHASE1 | Solid Tumor, Adult | TERMINATED | NCT05242822 |
| IPH5301 ALONE OR IN COMBINATION WITH CHEMOTHERAPY AND TRASTUZUMAB | DRUG | Phase PHASE1 | Metastatic Cancer | RECRUITING | NCT05143970 |
| Oxaliplatine | DRUG | Phase PHASE2 | Peripheral T Cell Lymphoma | RECRUITING | NCT04984837 |
| Gemcitabine | DRUG | Phase PHASE2 | Peripheral T Cell Lymphoma | RECRUITING | NCT04984837 |
| Lacutamab | DRUG | Phase PHASE2 | Peripheral T Cell Lymphoma | RECRUITING | NCT04984837 |
| Placebo | OTHER | Phase PHASE3 | Squamous Cell Carcinoma of the Head and Neck | ACTIVE_NOT_RECRUITING | NCT04590963 |
| avdoralimab | BIOLOGICAL | Phase PHASE2 | COVID | COMPLETED | NCT04371367 |
| draw blood | OTHER | Approved | COVID-19 | COMPLETED | NCT04369820 |
| IPH5401 and Durvalumab | BIOLOGICAL | Phase PHASE1 | Advanced Solid Tumors | TERMINATED | NCT03665129 |
| immunohistochemistry assay | OTHER | Preclinical | Solid Cancer | UNKNOWN | NCT03311100 |
| Surgery | PROCEDURE | Phase PHASE1 | Adenocarcinoma of the Esophagus | WITHDRAWN | NCT03307941 |
| Metabolic | OTHER | Phase PHASE1 | Adenocarcinoma of the Esophagus | WITHDRAWN | NCT03307941 |
| 5-Fluorouracil | DRUG | Phase PHASE1 | Adenocarcinoma of the Esophagus | WITHDRAWN | NCT03307941 |
| Oxaliplatin | DRUG | Phase PHASE1 | Adenocarcinoma of the Esophagus | WITHDRAWN | NCT03307941 |
| Anti-PD(L)1 | BIOLOGICAL | Phase PHASE1 | Head and Neck Neoplasms | COMPLETED | NCT02643550 |
| Cetuximab | DRUG | Phase PHASE3 | Squamous Cell Carcinoma of the Head and Neck | ACTIVE_NOT_RECRUITING | NCT04590963 |
| Monalizumab | DRUG | Phase PHASE3 | Squamous Cell Carcinoma of the Head and Neck | ACTIVE_NOT_RECRUITING | NCT04590963 |
| IPH4102 | BIOLOGICAL | Phase PHASE2 | Lymphoma, T-Cell | ACTIVE_NOT_RECRUITING | NCT03902184 |
| monalizumab | DRUG | Phase PHASE1 | Chronic Lymphocytic Leukemia | TERMINATED | NCT02557516 |
| Postsurgical Adjuvant Therapy | RADIATION | Phase PHASE1 | Squamous Cell Carcinoma of the Oral Cavity | TERMINATED | NCT02331875 |
| Standard Surgery | PROCEDURE | Phase PHASE1 | Squamous Cell Carcinoma of the Oral Cavity | TERMINATED | NCT02331875 |
| IPH2201 | DRUG | Phase PHASE1 | Gynecologic Cancer | COMPLETED | NCT02459301 |
| Placebo (normal saline solution) | DRUG | Phase PHASE2 | Acute Myeloid Leukemia | COMPLETED | NCT01687387 |
| IPH2102 at 1 mg/kg | DRUG | Phase PHASE2 | Acute Myeloid Leukemia | COMPLETED | NCT01687387 |
| IPH2102 at 0.1 mg/kg | DRUG | Phase PHASE2 | Acute Myeloid Leukemia | COMPLETED | NCT01687387 |
| Saline | DRUG | Phase PHASE2 | Secondary Progressive Multiple Sclerosis | COMPLETED | NCT02228213 |
| MIS416 | BIOLOGICAL | Phase PHASE2 | Secondary Progressive Multiple Sclerosis | COMPLETED | NCT02228213 |
| placebo | DRUG | Phase PHASE1 | Inflammation | COMPLETED | NCT01370902 |
| NNC 0141-0000-0100 | DRUG | Phase PHASE1 | Inflammation | COMPLETED | NCT01370902 |
| T gamma delta lymphocytes | OTHER | Phase PHASE1 | Hepatocellular Carcinoma | TERMINATED | NCT00562666 |
| IPH2101 combined to lenalidomide | DRUG | Phase PHASE1 | Patients With Multiple Myeloma Experiencing a | COMPLETED | NCT01217203 |
| IPH2101 | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT01256073 |
| Anti-KIR (1-7F9) | DRUG | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT00552396 |
Total products: 186